The further ROC analysis indicated that the ability of prokineticin 2 in separating the AIS patients with mRS score>2 compared with those with mRS score≤2 was weak [AUC (95% CI): 0.585 (0.482–0.687)] (Figure 3B). Here, PROK2 is linked to androgen insensitivity syndrome.